Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | The genomic landscape of driver events in MM

Francesco Maura • 13 Sep 2019
IMW 2019
Multiple Myeloma

Francesco Maura, MD Memorial Sloan Kettering Cancer Center, New York, NY, discusses a paper he recently published in nature which investigated the genomic landscape and chronological reconstruction of driver events in multiple myeloma (MM) at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Francesco Maura

Is high-risk smoldering myeloma a misnomer – do these patients already have myeloma? 2:02
Is high-risk smoldering myeloma a misnomer – do these patients already have myeloma?
Francesco Maura • 8 Dec 2025
Replacing standard FISH panels with WGS in multiple myeloma 1:49
Replacing standard FISH panels with WGS in multiple myeloma
Francesco Maura • 8 Dec 2025
Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more 13:45
Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more
Francesco Maura et al. • 24 Oct 2025
Two types of resistance to BCMA-directed treatments in multiple myeloma: how do they differ? 1:49
Two types of resistance to BCMA-directed treatments in multiple myeloma: how do they differ?
Francesco Maura • 19 Sep 2025

Related Videos

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals